The Institute of Cancer Research and Cancer Research Technology Limited (CRT), the technology transfer company of the charity Cancer Research UK, today announced the availability of free licences of European patents on the hereditary breast cancer gene BRCA2 to publicly funded research laboratories and not-for-profit research laboratories.
The patents are based on the pioneering work of Professor Mike Stratton undertaken at The Institute of Cancer Research and funded by CRT's parent charity, Cancer Research UK.
Further instructions for obtaining the licence can be found here: https://www.cancerresearchhorizons.com/our-portfolio/our-licensing-opportunities
Discover the innovations we have available for collaboration, that will help create the medicines of tomorrow.
We've played a role in delivering 14 new cancer treatments for patients. Explore our clinical and preclinical assets currently in development.
Discover our impact, and the differences we're aiming to make for people affected by cancer.
